Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Ligand Pharmaceuticals Incorporated (LGND) - Net Assets
Latest net assets as of September 2025: $950.17 Million USD
Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) has net assets worth $950.17 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.48 Billion) and total liabilities ($526.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $950.17 Million |
| % of Total Assets | 64.34% |
| Annual Growth Rate | 12.2% |
| 5-Year Change | 17.04% |
| 10-Year Change | 172.82% |
| Growth Volatility | 261.75 |
Ligand Pharmaceuticals Incorporated - Net Assets Trend (1994–2024)
This chart illustrates how Ligand Pharmaceuticals Incorporated's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ligand Pharmaceuticals Incorporated (1994–2024)
The table below shows the annual net assets of Ligand Pharmaceuticals Incorporated from 1994 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $830.44 Million | +18.48% |
| 2023-12-31 | $700.91 Million | +17.31% |
| 2022-12-31 | $597.49 Million | -27.24% |
| 2021-12-31 | $821.16 Million | +15.73% |
| 2020-12-31 | $709.52 Million | -7.52% |
| 2019-12-31 | $767.23 Million | +36.78% |
| 2018-12-31 | $560.91 Million | +33.98% |
| 2017-12-31 | $418.65 Million | +12.89% |
| 2016-12-31 | $370.85 Million | +21.83% |
| 2015-12-31 | $304.39 Million | +1147.10% |
| 2014-12-31 | $24.41 Million | -50.80% |
| 2013-12-31 | $49.61 Million | +87.32% |
| 2012-12-31 | $26.48 Million | +206.33% |
| 2011-12-31 | $8.65 Million | +223.67% |
| 2010-12-31 | $-6.99 Million | -286.73% |
| 2009-12-31 | $3.74 Million | +136.12% |
| 2008-12-31 | $-10.37 Million | -135.60% |
| 2007-12-31 | $29.11 Million | +6.45% |
| 2006-12-31 | $27.35 Million | +124.77% |
| 2005-12-31 | $-110.42 Million | -46.61% |
| 2004-12-31 | $-75.32 Million | -206.49% |
| 2003-12-31 | $70.73 Million | -4.44% |
| 2002-12-31 | $74.02 Million | +227.89% |
| 2001-12-31 | $-57.88 Million | -4.99% |
| 2000-12-31 | $-55.12 Million | -115.33% |
| 1999-12-31 | $-25.60 Million | -124.56% |
| 1998-12-31 | $-11.40 Million | -133.24% |
| 1997-12-31 | $34.30 Million | -0.58% |
| 1996-12-31 | $34.50 Million | +22.78% |
| 1995-12-31 | $28.10 Million | +6.84% |
| 1994-12-31 | $26.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ligand Pharmaceuticals Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 57508400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $498.98 Million | 60.09% |
| Common Stock | $20.00K | 0.00% |
| Other Comprehensive Income | $-5.94 Million | -0.72% |
| Other Components | $337.38 Million | 40.63% |
| Total Equity | $830.44 Million | 100.00% |
Ligand Pharmaceuticals Incorporated Competitors by Market Cap
The table below lists competitors of Ligand Pharmaceuticals Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hitachi Energy India Limited
NSE:POWERINDIA
|
$3.62 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
$3.62 Billion |
|
Vanguard International Semiconductor
TWO:5347
|
$3.62 Billion |
|
Abrdn PLC
PINK:SLFPF
|
$3.62 Billion |
|
Endeavour Group Limited
PINK:EDVGF
|
$3.62 Billion |
|
Gigabyte Technology Co Ltd
TW:2376
|
$3.61 Billion |
|
Shenzhen Capchem Tech
SHE:300037
|
$3.61 Billion |
|
Unifirst Corporation
NYSE:UNF
|
$3.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ligand Pharmaceuticals Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 700,913,000 to 830,439,000, a change of 129,526,000 (18.5%).
- Net loss of 4,032,000 reduced equity.
- Share repurchases of 5,136,000 reduced equity.
- New share issuances of 37,140,000 increased equity.
- Other comprehensive income decreased equity by 5,125,000.
- Other factors increased equity by 106,679,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.03 Million | -0.49% |
| Share Repurchases | $5.14 Million | -0.62% |
| Share Issuances | $37.14 Million | +4.47% |
| Other Comprehensive Income | $-5.12 Million | -0.62% |
| Other Changes | $106.68 Million | +12.85% |
| Total Change | $- | 18.48% |
Book Value vs Market Value Analysis
This analysis compares Ligand Pharmaceuticals Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23.08x to 4.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $9.14 | $210.99 | x |
| 1995-12-31 | $7.52 | $210.99 | x |
| 1996-12-31 | $7.19 | $210.99 | x |
| 1997-12-31 | $6.21 | $210.99 | x |
| 1998-12-31 | $-1.69 | $210.99 | x |
| 1999-12-31 | $-3.26 | $210.99 | x |
| 2000-12-31 | $-5.94 | $210.99 | x |
| 2001-12-31 | $-5.84 | $210.99 | x |
| 2002-12-31 | $6.42 | $210.99 | x |
| 2003-12-31 | $6.00 | $210.99 | x |
| 2005-12-31 | $-8.95 | $210.99 | x |
| 2006-12-31 | $2.04 | $210.99 | x |
| 2007-12-31 | $1.78 | $210.99 | x |
| 2008-12-31 | $-0.65 | $210.99 | x |
| 2009-12-31 | $0.20 | $210.99 | x |
| 2010-12-31 | $-0.36 | $210.99 | x |
| 2011-12-31 | $0.44 | $210.99 | x |
| 2012-12-31 | $1.33 | $210.99 | x |
| 2013-12-31 | $2.39 | $210.99 | x |
| 2014-12-31 | $1.23 | $210.99 | x |
| 2015-12-31 | $14.34 | $210.99 | x |
| 2016-12-31 | $17.80 | $210.99 | x |
| 2017-12-31 | $17.83 | $210.99 | x |
| 2018-12-31 | $23.31 | $210.99 | x |
| 2019-12-31 | $38.83 | $210.99 | x |
| 2020-12-31 | $43.84 | $210.99 | x |
| 2021-12-31 | $47.61 | $210.99 | x |
| 2022-12-31 | $35.42 | $210.99 | x |
| 2023-12-31 | $39.47 | $210.99 | x |
| 2024-12-31 | $45.40 | $210.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ligand Pharmaceuticals Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.41%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.13x
- Recent ROE (-0.49%) is below the historical average (11.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -103.04% | -203.76% | 0.28x | 1.78x | $-29.73 Million |
| 1995 | -228.47% | -262.04% | 0.26x | 3.33x | $-67.01 Million |
| 1996 | -108.12% | -101.36% | 0.36x | 2.96x | $-40.75 Million |
| 1997 | -292.13% | -193.81% | 0.48x | 3.13x | $-103.63 Million |
| 1998 | 0.00% | -666.10% | 0.11x | 0.00x | $-116.76 Million |
| 1999 | 0.00% | -182.64% | 0.30x | 0.00x | $-72.14 Million |
| 2000 | 0.00% | -150.44% | 0.42x | 0.00x | $-66.86 Million |
| 2001 | 0.00% | -56.32% | 0.65x | 0.00x | $-37.21 Million |
| 2002 | -44.04% | -33.73% | 0.36x | 3.66x | $-40.00 Million |
| 2003 | -52.97% | -26.54% | 0.47x | 4.26x | $-44.53 Million |
| 2005 | 0.00% | -20.61% | 0.56x | 0.00x | $-25.36 Million |
| 2006 | -116.05% | -22.52% | 0.43x | 11.92x | $-34.48 Million |
| 2007 | 967.50% | 2184.64% | 0.07x | 5.95x | $278.78 Million |
| 2008 | 0.00% | -359.19% | 0.16x | 0.00x | $-97.08 Million |
| 2009 | -52.03% | -5.00% | 0.34x | 30.37x | $-2.32 Million |
| 2010 | 0.00% | -53.17% | 0.31x | 0.00x | $-11.82 Million |
| 2011 | 117.70% | 33.88% | 0.25x | 14.15x | $9.31 Million |
| 2012 | -1.99% | -1.68% | 0.30x | 3.94x | $-3.18 Million |
| 2013 | 23.02% | 23.32% | 0.47x | 2.11x | $6.46 Million |
| 2014 | 45.69% | 18.63% | 0.25x | 9.80x | $9.39 Million |
| 2015 | 84.53% | 357.80% | 0.13x | 1.75x | $226.87 Million |
| 2016 | -0.44% | -1.50% | 0.18x | 1.62x | $-38.72 Million |
| 2017 | 3.00% | 8.90% | 0.21x | 1.60x | $-29.31 Million |
| 2018 | 25.55% | 57.00% | 0.20x | 2.25x | $87.23 Million |
| 2019 | 82.02% | 523.19% | 0.08x | 1.95x | $552.58 Million |
| 2020 | -0.42% | -1.82% | 0.12x | 1.92x | $-73.94 Million |
| 2021 | 6.96% | 23.66% | 0.19x | 1.58x | $-24.98 Million |
| 2022 | -5.58% | -17.00% | 0.26x | 1.28x | $-93.11 Million |
| 2023 | 7.44% | 39.72% | 0.17x | 1.12x | $-17.94 Million |
| 2024 | -0.49% | -2.41% | 0.18x | 1.13x | $-87.08 Million |
Industry Comparison
This section compares Ligand Pharmaceuticals Incorporated's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | $950.17 Million | -103.04% | 0.55x | $3.62 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |